Purple Biotech Q1 2024 GAAP EPADS $(0.14) Beats $(0.15) Estimate, Cash $9.985M
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech (NASDAQ:PPBT) reported Q1 2024 GAAP EPADS of $(0.14), beating the analyst consensus estimate of $(0.15) by 6.67%. This represents a 44% improvement over the $(0.25) loss per share from the same period last year. The company has $9.985M in cash.
May 21, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Purple Biotech reported a Q1 2024 loss of $(0.14) per share, beating estimates and showing a significant improvement from last year. The company also has $9.985M in cash.
The better-than-expected earnings per share and significant year-over-year improvement are positive indicators for the stock. The cash reserves also provide a cushion for future operations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100